Profile data is unavailable for this security.
About the company
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.
- Revenue in USD (TTM)6.74m
- Net income in USD-76.70m
- Incorporated2017
- Employees73.00
- LocationArbutus Biopharma Corp701 Veterans CircleWARMINSTER 18974United StatesUSA
- Phone+1 (267) 469-0914
- Fax+1 (604) 419-3201
- Websitehttps://www.arbutusbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunome Inc | 10.13m | -305.35m | 586.73m | 55.00 | -- | 2.65 | -- | 57.93 | -6.06 | -6.06 | 0.1889 | 3.56 | 0.0579 | -- | -- | 184,163.60 | -174.46 | -94.54 | -212.48 | -112.66 | -- | -- | -3,014.59 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
| Mineralys Therapeutics Inc | 0.00 | -153.25m | 590.26m | 28.00 | -- | 2.49 | -- | -- | -3.27 | -3.27 | 0.00 | 4.76 | 0.00 | -- | -- | 0.00 | -56.16 | -- | -61.19 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| Stoke Therapeutics Inc | 16.74m | -105.46m | 596.94m | 110.00 | -- | 2.57 | -- | 35.65 | -2.10 | -2.10 | 0.3294 | 4.38 | 0.0628 | -- | 42.55 | 152,209.10 | -39.56 | -31.62 | -46.04 | -33.92 | -- | -- | -629.86 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
| Altimmune Inc | 52.00k | -103.52m | 597.35m | 59.00 | -- | 4.48 | -- | 11,487.53 | -1.55 | -1.55 | 0.0008 | 1.88 | 0.0003 | -- | 0.0798 | 881.36 | -65.84 | -39.62 | -70.44 | -42.58 | -- | -- | -199,076.90 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| Dianthus Therapeutics Inc | 5.37m | -67.09m | 599.93m | 53.00 | -- | 1.76 | -- | 111.80 | -2.49 | -2.49 | 0.1968 | 11.51 | 0.0196 | -- | 3.13 | 101,245.30 | -24.54 | -41.40 | -25.91 | -44.70 | -- | -- | -1,250.32 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -119.87m | 643.35m | 112.00 | -- | 2.35 | -- | -- | -1.81 | -1.81 | 0.00 | 3.88 | 0.00 | -- | -- | 0.00 | -41.59 | -33.92 | -44.71 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
| AnaptysBio Inc | 57.17m | -165.66m | 644.18m | 117.00 | -- | 7.64 | -- | 11.27 | -6.07 | -6.07 | 2.09 | 2.77 | 0.1166 | -- | 7.39 | 488,649.60 | -33.78 | -18.08 | -36.91 | -18.96 | -- | -- | -289.75 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
| Adaptive Biotechnologies Corp | 177.28m | -195.24m | 644.92m | 709.00 | -- | 2.88 | -- | 3.64 | -1.34 | -1.34 | 1.21 | 1.52 | 0.2778 | 4.68 | 4.92 | 250,045.10 | -30.61 | -19.69 | -35.66 | -22.06 | 58.46 | 67.18 | -110.19 | -122.27 | 3.38 | -- | 0.3725 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
| Arbutus Biopharma Corp | 6.74m | -76.70m | 655.64m | 73.00 | -- | 6.13 | -- | 97.25 | -0.4259 | -0.4259 | 0.0374 | 0.5643 | 0.0451 | -- | 3.57 | 92,356.16 | -51.29 | -52.62 | -59.50 | -58.11 | -- | -- | -1,137.65 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| BIOAGE Labs Inc | 0.00 | -62.16m | 661.05m | 58.00 | -- | -- | -- | -- | -1.82 | -1.82 | 0.00 | 4.26 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -4.99 | 0.0724 | -- | -- | -- | -60.75 | -- | -- | -- |
| Tectonic Therapeutic Inc | 0.00 | -54.39m | 661.43m | 13.00 | -- | 4.40 | -- | -- | -13.91 | -13.91 | 0.00 | 10.20 | 0.00 | -- | -- | 0.00 | -38.96 | -45.22 | -42.77 | -49.14 | -- | -- | -- | -- | -- | -- | 0.0066 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
| Entrada Therapeutics Inc | 215.23m | 54.95m | 675.43m | 177.00 | 11.32 | 1.60 | 11.55 | 3.14 | 1.59 | 1.59 | 5.97 | 11.30 | 0.4141 | -- | 56.43 | 1,353,660.00 | 10.57 | -- | 13.68 | -- | -- | -- | 25.53 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| Cullinan Therapeutics Inc | 0.00 | -143.54m | 711.54m | 85.00 | -- | 1.13 | -- | -- | -2.88 | -2.88 | 0.00 | 10.80 | 0.00 | -- | -- | 0.00 | -25.35 | -12.37 | -26.45 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| Oruka Therapeutics Inc | 0.00 | -7.20m | 717.47m | 4.00 | -- | 0.7608 | -- | -- | -5.97 | -5.97 | 0.00 | 26.94 | 0.00 | -- | -- | 0.00 | -19.22 | -27.78 | -19.99 | -29.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 46.21 | -- | -- | -- |
| CARGO Therapeutics Inc | 0.00 | -154.14m | 722.08m | 116.00 | -- | 1.80 | -- | -- | -3.43 | -3.43 | 0.00 | 8.72 | 0.00 | -- | -- | 0.00 | -57.80 | -- | -65.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Arbutus Biopharma Corp's reporting currency: US Dollar USD
40.65%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Morgan Stanley Investment Management, Inc.as of 30 Sep 2024 | 20.03m | 10.61% |
| Whitefort Capital Management, LPas of 30 Sep 2024 | 12.87m | 6.82% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 11.13m | 5.90% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 8.49m | 4.50% |
| Two Seas Capital LPas of 30 Sep 2024 | 8.39m | 4.44% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 4.41m | 2.34% |
| Geode Capital Management LLCas of 30 Sep 2024 | 3.45m | 1.83% |
| FourWorld Capital Management LLCas of 30 Sep 2024 | 2.97m | 1.58% |
| Adage Capital Management LPas of 30 Sep 2024 | 2.90m | 1.54% |
| Adar1 Capital Management LLCas of 30 Sep 2024 | 2.09m | 1.11% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
